Merck Sharp + Dohme Corp.

Mochida Pharmaceutical Co., Ltd.

Mochida Paraceuticals Co., Ltd.

Mochida Pharmacuetical Co., Ltd.

Ting Zhang

Liangqin Guo

Deping Wang

Mark E Layton

Thomas J Greshock

Ronald M Kim

Anthony J Roecker

Cameron James Smith

Jiayi Xu

Walter Won

Tianying Jian

Tomokazu Hirabayashi

Philippe G Nantermet

Rajan Anand

Yi-Heng Chen

James J Mulhearn

Michael J Kelly, Iii

Gang Zhou

Hiroshi Nagasue

Isao Sakurada

William J Greenlee

Samuel Chackalamannil

James M Balkovec

Harold B Wood

Takashi Mizuno

Dongfang Meng

Yili Chen

John Qiang Tan

Dann Parker

Yoshitaka Maeda

Younong Yu

Jian Liu

James J Perkins

Jason M Cox

Christopher S Burgey

Hong Liu

Shawn P Walsh

Alan W Hruza

Helen Y Chen

Bing Li

Richard Berger

Manuel De Lera Ruiz

Junying Zheng

Christopher James Bungard

John E Stelmach

Hong Li

Dann LeRoy Parker, Jr

Mehul F Patel

Robert Kevin Orr

Edward C Sherer

Bart Harper

Joseph E Pero

Meng Yang

Jane Yang Wu

Louis-Charles Campeau

Kouki Ogawa

Sunita V Dewnani

Mika Sekioka

Dann L Parker

William John Greenlee

Michael J Iii Kelly

Mika Katsuno

Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and Rto Rare defined herein, which compounds have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same. 

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same. 

Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-1 or their salts, and methods of treating pain (e.g. chronic pain), or cough or itch disorders using the same. 

N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors. 

Factor IXa inhibitors

Disclosed are compounds of Formula A, or a salt thereof: wherein R, R, and E are defined herein, which compounds have properties for inhibiting Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.

Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels

The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors. 

In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes. 

The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula I, and methods for using compounds of Formula I for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.

The present invention provides a compound of Formula (I) wherein

Growing community of inventors

Princeton Junction, NJ, United States of America

Ting Zhang